CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93) |
| |
Authors: | von Minckwitz Gunter Graf Erika Geberth Matthias Eiermann Wolfgang Jonat Walter Conrad Bettina Brunnert Klaus Gerber Bernd Vescia Sabine Wollert Jörg Kaufmann Manfred |
| |
Institution: | German Breast Group, Schleussnerstrase 42, 63263 Neu-Isenburg, Germany. Minckwitz@germanbreastgroup.de |
| |
Abstract: | Gonadotrophin-releasing hormone analogues were investigated as adjuvant treatment for patients with node-negative, hormone-sensitive, premenopausal breast cancer. Patients were randomised to either three cycles of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy (n=378) or goserelin every 28 d for 2 years (n=393). During a median follow-up of 4.9 years, 123 events were observed. The first-failure event of CMF versus goserelin, respectively, was ipsilateral locoregional recurrence (18 versus 20), contralateral breast cancer (7 versus 6), distant failure (35 versus 24) and death without recurrence (2 versus 2). Forty-two (23 versus 19) deaths of any cause occurred. The estimated adjusted hazard ratio for goserelin versus CMF (intention-to-treat analysis) was 0.79 (95% CI=0.54-1.14; P=0.19). It is concluded that medical ovarian ablation with goserelin represents a valid option for premenopausal patients with node-negative breast cancer. |
| |
Keywords: | |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|